Dopamino agonisti per la malattia di Parkinson e danno alle valvole cardiache Gianni Pezzoli

1. Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, Sanvikarja S, van Puijenbroek EP, Stricker BH. Pergolide-induced pleuropulmonary fibrosis. Clin Neuropharmacol 2002; 25: 290-293
2. Flowers CM, Racoosin JA, Lu SI, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003;78:730-731.
2. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
3. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
4. Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-304.
5. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662.
6. Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 2005;353:1976-1977.
7. Serratrice J, Disdier P, Habib G, Viallet F, Weiller P. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 2002;10:334-336.
8. Rascol O, Pathak A, Bagheri H, Montastruc JL. New concerns about old drugs: valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord 2004;19:611-613.
9. Dhawean V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P, Odin P, Chaudhuri KR. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. J Neural Transm 2005; 112: 661-668
10. Chaudhuri KR, Dhavan V, Basu S, Jackson G, Odin P. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared. Mov Disord 2004;19:1522-1523.
11. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve disease associated with with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 1992;117:50-52.
12. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 1999;100:2161-2167.
13. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 2000;101:2071-2077.
14. Botero M, Fuchs R, Paulus DA, Lind DS. Carcinoid heart disease: a case report and literature review. J Clin Anesth 2002;14:57-63.
15. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New Engl J Med 2007; 356: 39-46
13. Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
14. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38
17. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007: 356: 6-9
18. Farmacovigilanza. Analisi dei segnali: cabergolina e valvulopatie cardiache. BIF XIII 2006; 4: 161-163